Benito Chiofalo1, Ivano Mazzon1, Silvia Di Angelo Antonio1, Donatella Amadore1, Enrico Vizza1, Antonio Simone Laganà2, Giuseppe Vocaturo1, Gloria Calagna1, Alessandro Favilli1, Vittorio Palmara1, Marianna Maranto1, Salvatore Giovanni Vitale1, Gaspare Cucinella1, Roberta Granese1, Fabio Ghezzi1, Isabella Sperduti1, Onofrio Triolo1. 1. Gynecologic Oncology Unit, Department of Experimental Clinical Oncology, IRCCS Regina Elena National Cancer Institute, Rome, Italy (Drs. Chiofalo, Vizza, and Vocaturo); Arbor Vitae Centre, Nuova Villa Claudia Clinic, Rome, Italy (Drs. Mazzon and Di Angelo Antonio); Unit of Gynecology and Obstetrics, Department of Human Pathology in Adulthood and Childhood "G. Barresi," University of Messina, Messina, Italy (Drs. Amadore, Palmara, Granese, and Triolo); Department of Obstetrics and Gynecology, Filippo Del Ponte Hospital, University of Insubria, Varese, Italy (Drs. Laganà and Ghezzi); Gynecology and Obstetrics Unit, Villa Sofia-Cervello Hospital, University of Palermo, Palermo, Italy (Drs. Calagna, Maranto, and Cucinella); Department of Surgical and Biomedical Sciences, Section of Obstetrics and Gynecology, S. Maria della Misericordia Hospital, University of Perugia, Perugia, Italy (Dr. Favilli); Department of General Surgery and Medical Surgical Specialties, University of Catania, Catania, Italy (Dr.Vitale); Biostatistical Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy (Dr. Sperduti). 2. Gynecologic Oncology Unit, Department of Experimental Clinical Oncology, IRCCS Regina Elena National Cancer Institute, Rome, Italy (Drs. Chiofalo, Vizza, and Vocaturo); Arbor Vitae Centre, Nuova Villa Claudia Clinic, Rome, Italy (Drs. Mazzon and Di Angelo Antonio); Unit of Gynecology and Obstetrics, Department of Human Pathology in Adulthood and Childhood "G. Barresi," University of Messina, Messina, Italy (Drs. Amadore, Palmara, Granese, and Triolo); Department of Obstetrics and Gynecology, Filippo Del Ponte Hospital, University of Insubria, Varese, Italy (Drs. Laganà and Ghezzi); Gynecology and Obstetrics Unit, Villa Sofia-Cervello Hospital, University of Palermo, Palermo, Italy (Drs. Calagna, Maranto, and Cucinella); Department of Surgical and Biomedical Sciences, Section of Obstetrics and Gynecology, S. Maria della Misericordia Hospital, University of Perugia, Perugia, Italy (Dr. Favilli); Department of General Surgery and Medical Surgical Specialties, University of Catania, Catania, Italy (Dr.Vitale); Biostatistical Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy (Dr. Sperduti). Electronic address: antoniosimone.lagana@uninsubria.it.
Abstract
STUDY OBJECTIVE: The primary aim of our study was to investigate the incidence of endometrial pathologies, especially endometrial cancer, in women with breast cancer treated with tamoxifen (TAM), aromatase inhibitors (AIs), or receiving no treatment (NT). The secondary aim was to identify, in this cohort, ultrasonographic findings that represent robust indications for hysteroscopy and endometrial biopsy, to avoid unnecessary second-level diagnostic procedures. DESIGN: Multicenter retrospective cohort study (Clinical Trial ID: NCT03898947). SETTING: Data were collected from different Italian centers: Regina Elena National Cancer Institute of Rome, Arbor Vitae Centre of Rome, Gaetano Martino University Hospital of Messina, and Villa Sofia-Cervello Hospital of Palermo. PATIENTS: We selected and consecutively included patients with a history of breast cancer who had undergone hysteroscopy for ultrasonographic or clinical indications between January 2007 and December 2016. INTERVENTIONS: Diagnostic hysteroscopy with endometrial biopsy or operative hysteroscopy, when clinically indicated. MEASUREMENTS AND MAIN RESULTS: A higher percentage of patients in the TAM and AI groups had a normal endometrium compared with those in the NT group, whereas the incidence of endometrial polyps was higher in the NT group than in the others; no significant differences were observed among the 3 groups for other benign conditions or for premalignant and malignant uterine diseases, such as endometrial atypical hyperplasia and adenocarcinoma. CONCLUSION: TAM treatment does not seem to be associated with a higher rate of endometrial cancer in women with breast cancer compared with women treated with AIs or NT.
STUDY OBJECTIVE: The primary aim of our study was to investigate the incidence of endometrial pathologies, especially endometrial cancer, in women with breast cancer treated with tamoxifen (TAM), aromatase inhibitors (AIs), or receiving no treatment (NT). The secondary aim was to identify, in this cohort, ultrasonographic findings that represent robust indications for hysteroscopy and endometrial biopsy, to avoid unnecessary second-level diagnostic procedures. DESIGN: Multicenter retrospective cohort study (Clinical Trial ID: NCT03898947). SETTING: Data were collected from different Italian centers: Regina Elena National Cancer Institute of Rome, Arbor Vitae Centre of Rome, Gaetano Martino University Hospital of Messina, and Villa Sofia-Cervello Hospital of Palermo. PATIENTS: We selected and consecutively included patients with a history of breast cancer who had undergone hysteroscopy for ultrasonographic or clinical indications between January 2007 and December 2016. INTERVENTIONS: Diagnostic hysteroscopy with endometrial biopsy or operative hysteroscopy, when clinically indicated. MEASUREMENTS AND MAIN RESULTS: A higher percentage of patients in the TAM and AI groups had a normal endometrium compared with those in the NT group, whereas the incidence of endometrial polyps was higher in the NT group than in the others; no significant differences were observed among the 3 groups for other benign conditions or for premalignant and malignant uterine diseases, such as endometrial atypical hyperplasia and adenocarcinoma. CONCLUSION:TAM treatment does not seem to be associated with a higher rate of endometrial cancer in women with breast cancer compared with women treated with AIs or NT.
Authors: Francesca Pellini; Giacomo Di Filippo; Sara Mirandola; Giulia Deguidi; Elisa Filippi; Giovanni Paolo Pollini Journal: Front Surg Date: 2021-03-11
Authors: Norbert Stachowicz; Agata Smoleń; Michał Ciebiera; Tomasz Łoziński; Paweł Poziemski; Dariusz Borowski; Artur Czekierdowski Journal: Diagnostics (Basel) Date: 2021-03-04
Authors: Salvatore Giovanni Vitale; Gaetano Riemma; Jose Carugno; Benito Chiofalo; George Angelos Vilos; Stefano Cianci; Mehmet Sukru Budak; Bernardo Portugal Lasmar; Antonio Raffone; Ilker Kahramanoglu Journal: Transl Cancer Res Date: 2020-12 Impact factor: 1.241